There is increasing evidence showing that the stromal cells surrounding cancer epithelial cells, rather than being passive bystanders, might have a role in modifying tumor outgrowth. The molecular basis of this aspect of carcinoma etiology is controversial. Some studies have reported a high frequency of genetic aberrations in carcinoma-associated fibroblasts (CAFs), whereas other studies have reported very low or zero mutation rates. Resolution of this contentious area is of critical importance in terms of understanding both the basic biology of cancer as well as the potential clinical implications of CAF somatic alterations. We undertook genome-wide copy number and loss of heterozygosity (LOH) analysis of CAFs derived from breast and ovarian carcinomas using a 500K SNP array platform. Our data show conclusively that LOH and copy number alterations are extremely rare in CAFs and cannot be the basis of the carcinoma-promoting phenotypes of breast and ovarian CAFs.
Molecular studies of carcinomas have predominantly focused on the elucidation of the events arising in the cancerous epithelial cells, and little attention has been given to the role of the surrounding stromal cell population. Recent evidence shows that stromal cells may not be passive bystanders but might have an important role in modifying tumor growth. Many functional studies have demonstrated the importance of fibroblasts in cancer initiation 1 , progression [2] [3] [4] and metastases 5 . In animal models of prostate and breast cancers, oncogene-modified epithelial cells became malignant or showed enhanced growth when co-inoculated with fibroblasts that were either oncogene induced 6 or derived from fresh human carcinoma tissues 2, 3 (that is, CAFs).
Of note, in these studies, the tumor-enhancing behavior of CAFs was stably maintained even without continued exposure to cancer cells. These observations implied that genetic or epigenetic alterations might underlie this stable phenotype, and invoked the provocative hypothetical interdependent co-evolution of somatic changes in cancer and CAFs 7 . Indeed, some studies have reported a high frequency of genetic aberrations such as gene copy number alterations, loss of heterozygosity, microsatellite instability and point mutations in tumor suppressor genes and oncogenes in CAFs derived from various human cancers [8] [9] [10] [11] . Notably, in some studies, the frequency of LOH was reported to be similar to that observed in the epithelial components. For example, average marker-specific LOH frequencies of 59.7% and 28.4% have been reported in CAFs derived from BRCA1/2-related and sporadic breast carcinomas, respectively 12, 13 . Moreover, a significant association between the CAF LOH signature and tumor grade and lymph node metastasis has been reported in women diagnosed with sporadic breast tumors 14 . In addition, up to 63% of ovarian CAFs have been reported to show LOH at 3p21 (ref. 15) . The same investigators subsequently assessed copy number changes at 110 loci and observed that approximately 10.8 genes had undergone copy number changes in each ovarian CAF 15, 16 .
However, not all studies have identified genetic alterations in CAFs; for example, one study did not find any clonally selected somatic genetic alterations in CAFs separated from fresh breast cancer biopsies using array comparative genomic hybridization (CGH) and SNP array analysis 17 , although these CAFs were epigenetically distinct from those from normal breast tissue, as demonstrated by subsequent genomewide DNA methylation studies 18 .
The evidence for somatic genetic alterations as important mediators of the CAF phenotype is controversial and conflicting. We hypothesized that the contradictory data may in part be a reflection of inherent technical limitations of the various methodologies used. Therefore, we took advantage of innovative SNP array-based technologies 19 to investigate in detail the genomic integrity of CAFs microdissected from fresh frozen primary human ovarian and breast cancers as well as short-term cultures of primary breast CAFs.
We assessed the sensitivity of the Affymetrix 500K SNP array platform to detect copy number and LOH in the context of normal DNA contamination in a mixing experiment using tumor epithelial cell DNA from a microdissected primary ovarian cancer that was mixed with various ratios of matched normal DNA. This tumor harbors a complex copy number profile on chromosome 17, including regions of high level copy number gain and regions of LOH with and Figure 2 Genome-wide copy number and LOH analysis plot of different cell types within medullary breast cancer sample P5077. DNA of epithelial and stromal cell components were independently analyzed on 500K SNP arrays, and the results were normalized to corresponding normal blood DNA. Purple line is a plot of a 20-SNP moving average of the log2 copy number ratios. Blue and red lines represent allele-specific log2 copy numbers with a value of 0 being equivalent to 1 copy, and a value of -1 equivalent to complete loss of the allele. Note the region of copy number-neutral LOH on chromosome 3p in tumor P5077T (black arrow) as indicated by a near diploid copy number (purple line), whereas the allele-specific copy number shows loss of one allele and a corresponding gain of the other allele. without associated copy number loss. As shown in Supplementary  Figure 1a online, the single copy number gain was clearly visible at 70% tumor DNA, and the high level gain was still discernible at 25% tumor DNA. LOH was also discernible at least down to 70% tumor as indicated by the divergence of the allele-specific copy number traces, consistent with previous validations of this array platform 20, 21 . For all cases, only areas of stroma that were located within 5 mm distance of the cancer epithelial compartment were needle microdissected from 10 mm thick fresh frozen sections. A typical example of an ovarian and breast cancer specimen before and after microdissection is shown in Figure 1a and 1b, respectively. As stroma can comprise many different cell types, microdissected areas were assessed by two independent pathologists to estimate the percentage of fibroblast cells in each preparation. The microdissected areas of stroma from 20 of 25 of the ovarian cancers were estimated to contain Z70% fibroblast (Supplementary Table 1 online), whereas the microdissected areas of stroma from all ten of the breast cancers were estimated to contain Z75% fibroblast (Supplementary Table 2 online) .
Using SNP array analysis, we identified a high frequency of copy number changes and LOH in each of the 10 breast tumor and 25 ovarian epithelia (examples shown in Figs. 2 and 3) . By contrast, none of the breast CAF preparations showed any evidence of copy number gain or loss, or LOH on any chromosome (Fig. 2b) . Similarly, 24 of 25 of the ovarian CAF preparations showed a normal genomic profile (Fig. 3b) . One ovarian CAF sample (from case IC307) did show LOH, coupled with copy number loss of the entire chromosome 22 (Fig. 4a) . Of note, the tumor epithelium also showed loss of chromosome 22; however, there was a small region of copy number gain near the centromere. This suggests that the loss observed in the CAF component was not simply due to contamination from the epithelial component. To validate the loss of chromosome 22 in this CAF preparation, we microdissected a total of four tumor foci and six CAF foci taken from the original tumor block, as well as additional three independent tumor blocks (examples shown in Fig. 4b,c) , and analyzed the DNA for allelic imbalance using microsatellite markers (MSMs). Analysis with D22S1169 showed that every tumor focus showed loss of the larger allele (Fig. 4d) . We examined a total of six CAF foci and found that three showed allelic imbalance, but of the allele opposite to that of the tumor foci. The other three CAF foci retained heterozygosity with D22S1169. Notably, on the same block, one CAF focus (F2b) showed allelic imbalance, whereas the other focus (F2a) retained heterozygosity (Fig. 4d ). An identical pattern of allelic imbalance was observed with D22S1174 (data not shown).
We analyzed DNA from seven short-term cultured breast CAF populations for copy number alterations. Six of the fibroblast cultures showed no evidence of copy number alterations or LOH (for example, IDC-14; Fig. 5a ). One fibroblast culture (IDC-1819) showed gain of chromosomes 7 and 10 ( Fig. 5b) with a mean copy number of approximately 2.3. The data suggests that this CAF culture is comprised of a mixture of predominantly diploid cells plus a small subpopulation of cells containing three or possibly more copies of chromosomes 7 and 10. Matching normal DNA was not available for this case, but given the extent of the alteration and the fact that it was present only in a small proportion of the cells, it is unlikely that this could represent a germline variation. Therefore, it probably represents a somatic event that either was present in the original primary fibroblast cells or, more likely, arose during the short-term culture process.
Previous studies have reported the existence of CAF mutation hot spots with specific MSMs showing LOH frequencies of up to 63% on chromosome 3 in ovarian cancer 15 and up to 50% on chromosome 11 
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in breast cancer 13, 14 . Even though the SNP array data indicated a 0% frequency of LOH or copy number loss at these loci, we nevertheless sought to verify this by analyzing the allelic imbalance status using five MSMs identical to those previously reported and one additional MSM located within the hot-spot region. DNA was available from 12 primary ovarian CAFs, eight primary breast CAFs and four cultured breast CAFs for this analysis. No evidence of allelic imbalance was shown in any of the ovarian CAFs, but allelic imbalance was readily detected on chromosome 3 in 9 of 12 (75%) paired ovarian tumor epithelia, an example of which is shown in Figure 6a . Furthermore, none of the 12 breast CAF populations showed any evidence of allelic imbalance, whereas three of ten (30%) available paired breast tumor epithelia showed allelic imbalance (Fig. 6b) . In our view, previous studies reporting either the absence or frequent occurrence of genetic alterations in CAFs had significant technical limitations. In particular, studies reporting exceptionally high frequencies of alterations have relied exclusively on microdissection from formalin-fixed paraffin-embedded (FFPE) cancer tissues followed by highly multiplexed PCR-based microsatellite analysis. It is well established that the quality and quantity of DNA accessible from FFPE tissues may be suboptimal for reliable assessment of allelic imbalance [22] [23] [24] . Figure 6 Assessment of allelic imbalance at stroma-specific mutation hot spots in ovarian cancer sample IC293 and breast cancer sample P5077. The CNAG copy number plots of the 500K SNP array data for the tumor and fibroblast components are shown at the top of each figure, and the MSM chromatograms are shown below. Locations of the MSMs relative to the CNAG plot are indicated by arrows. The allelic imbalance ratio for each tumor and stroma sample was calculated in comparison with corresponding normal DNA and is listed under each chromatogram. Allelic imbalance is considered significant when the allelic imbalance ratio was r0.67 or Z1.5 (indicated by red asterisk). (a) Allelic imbalance analysis of ovarian cancer sample IC293 using three chromosome 3 MSMs: D3S3640, D3S1613 and D3S1744. Allelic imbalance is evident in the tumor component for all 3 MSMs, which is consistent with the SNP array data. There is no evidence of allelic imbalance in the fibroblast preparations with any MSMs. (b) Allelic imbalance analysis of breast cancer 5077 using three chromosome l1 MSMs: D11S1999, D11S2365 and D11S2002. The tumor component shows allelic imbalance with MSMs D11S1999 and D11S2002, but retention of heterozygosity with D11S2365 that is consistent with the prediction of 500K SNP array data (see allelespecific copy number plot, blue and red lines). There is no evidence of allelic imbalance in the fibroblast samples with any MSMs. Consequently, we undertook a careful examination of CAFs from breast and ovarian cancers using tissues and techniques that minimize the potential of false-positive and false-negative data. First, we exclusively used fresh frozen cancer tissues. Second, we used microdissection to obtain CAF populations that were largely free of nonfibroblast cells ( Supplementary Tables 1 and 2 ) and that were within 5 mm distance of the epithelial compartment of the carcinoma. It is reasonable to assume the presence of some adjacent nonneoplastic and nonfibroblast cells within the 5 mm distance of the epithelial compartment of the carcinoma, but this problem would be shared by all published results, including this work. Third, we used ultra high-resolution SNP arrays, which can simultaneously detect copy number alterations and LOH events with high precision and sensitivity 19, 20 .
In contrast to previous studies in ovarian cancer 15, 16 and breast cancer 13, 14 , our study did not find any evidence of frequent somatic genetic alterations in CAFs from either cancer type. The sole confirmed somatic genetic alteration was detected in an endometrioid ovarian cancer, which showed copy number loss of the entire chromosome 22. This case underscores the fact that somatic alterations can be readily detected in CAFs using the SNP array technology but also highlights the reality that such alterations are extremely rare. The chromosome 22 loss in this case does not necessarily impute a cancer-promoting phenotype for this CAF population, as it might be due to a random and benign alteration that occurred in a fibroblast stem cell.
Our study also included seven primary CAF cultures, for which the phenotypes can potentially be examined. According to our findings, only one of seven primary CAF cultures showed copy number alterations of chromosome 7 and 10 in a subpopulation of cells. Notably, we found that four of the CAF cultures without any detectable somatic changes promoted tumor growth more efficiently than normal breast stromal fibroblasts in xenograft assays (Supplementary Table 3 online) . Tumor fibroblast cultures were tested for the methylation and expression of Cxorf12, a gene we had previously found to be abnormally methylated and silenced in breast tumor stroma compared to normal breast stroma 18 . All samples showed different methylation and expression patterns compared to their normal counterparts (when applicable), although variation among samples existed ( Supplementary Fig. 2 online and Supplementary  Table 3) . Thus, the results of these assays confirmed the abnormal phenotype of the CAF cultures in the absence of somatic genetic changes.
In conclusion, we have conducted the highest resolution analysis of breast and ovarian CAFs reported to date. We have used tissues, technologies and methodologies that overcome the potential weaknesses of previous investigations that have produced sharply conflicting evidence for the existence of somatic genetic alterations in CAFs. Our data show that although somatic alterations can occur in CAFs, they are exceedingly rare and are unlikely to be responsible for the stable cancer-promoting attributes of CAFs. However, our findings cannot exclude the possibility that other mechanisms, such as epigenetic changes, have a role in the tumor-promoting phenotype of CAFs 18, 25 .
METHODS
Human tissue samples. We obtained 25 fresh frozen ovarian carcinoma biopsies from women undergoing surgery for primary epithelial ovarian cancer at hospitals in the south of England 26 , and ten fresh frozen breast carcinoma biopsies from the Peter MacCallum Cancer Centre tissue bank or the Victorian Breast Cancer Research Consortium tissue bank. We extracted matching normal DNA for both the breast and ovarian cancers cases from peripheral blood lymphocytes or normal breast tissue. All the biopsies were collected with informed consent, and this study was approved by the Peter MacCallum Cancer Centre Human Research Ethics Committee. Clinicopathological details of the ovarian and breast cancer subjects are described in Supplementary Tables 1  and 2 , respectively.
Tissue microdissection and DNA extraction. We stained 7-20 sequential 10 mm thick sections from each fresh frozen tumor biopsy with hematoxylin and eosin. All cases were reviewed by two pathologists to confirm the cancer diagnosis and to identify tumor epithelial and CAF regions suitable for microdissection. Tissue sections were then visualized under a dissecting microscope, and tumor epithelia and surrounding stroma were microdissected using an 18 gauge needle as described previously 26 . Only CAFs that were located within 5 mm distance from the tumor epithelial compartment were microdissected. We extracted DNA using the Blood and Tissue DNeasy kit (Qiagen) according to manufacturer's instructions.
Primary culture of breast CAF samples. We purified six breast CAFs from human tumors essentially as previously described 17 . Primary cultures of fibroblasts were initiated and maintained in DMEM medium (Invitrogen) supplemented with 10% iron-fortified bovine calf serum (Hyclone) and penstrep (Invitrogen). One breast CAF culture was prepared independently as previously described 27 . Details on the source of the CAF cultures are provided in Supplementary Table 3 .
Human mapping 500K SNP array analyses. High-throughput microarray genotyping analysis was done for each tumor epithelia, corresponding stroma, and matched normal DNA using GeneChip Human Mapping 250K Arrays NspI and/or StyI (Affymetrix) following manufacturer's instructions and as described previously 19 . We analyzed 28 of ovarian and breast fresh frozen samples with both chips, and the primary breast CAFs on the NspI array only. The standard probe generation assay utilizes 250 ng of input DNA per array, but this provides an amount of labeled probe that is well in excess of what is required. Therefore, in 30 of 193 (15.5%) of analyzed cases where DNA was limiting, we used an input of 75 ng of DNA instead. In these cases, we carried out the restriction digestion and ligation in three-tenths volume of the standard protocol. In both circumstances, all subsequent steps followed the standard protocol.
Microarray analysis. Data were first analyzed in GTYPE v4.0 (Affymetrix) to generate genotype information. The mapping algorithm call threshold setting was set at 0.26. Copy number information was derived after first normalizing each tumor to its matched normal in CNAG v2.0 (ref. 28) . For samples that did not have a matching normal, we generated the copy number plot by normalizing them to five unmatched normal references, which gave a o0.3 standard deviation. For samples analyzed on both the 250K StyI and 250K NspI arrays, we combined data from the two arrays. Regions of copy number gains and losses were visually identified and confirmed by interrogation of the raw copy number log 2 ratios from CNAG v2.0 (ref. 28) . The datasets were also analyzed using DNA-chip analyzer (dCHIP) to assess LOH and copy number changes 29 .
Microsatellite analysis. We used eight microsatellite markers (MSMs) spanning 3p14.3, p21.3 and 3q24 (D3S1613, D3S3640 and D3S1744), 11p15.1, 11q11 and q14.1 (D11S1999, D11S2365 and D11S2002) and 22q11.23 and q13.32 (D22S1174 and D22S1169) to analyze allelic imbalance. The primer sequences were obtained from The Human Genome Database and are listed in Supplementary Table 4 online. We amplified the target sequences in a total volume of 10 ml, containing 1Â PCR reaction buffer, 0.2 mM dNTPs, 0.25 mM forward and reverse primers and 0.25 U HotStar Taq polymerase (Qiagen). Fragment analysis was done using an ABI 3130 DNA analyzer (Applied Biosystems). The genotyping results were analyzed by automated fluorescence detection using ABI GeneMapper v3.7 (Applied Biosystems). Allelic imbalance is considered significant when allelic ratio is r0.67 or Z1.5, as described previously 14 .
Quantitative methylation-specific PCR (qMSP) and quantitative RT-PCR (qRT-PCR). Genomic DNA was bisulfite-treated and purified, and quantitative
